MRONJ Flashcards
what is the initial management of patients at risk of MRONJ
get as dentally fit as possible
advise of the risk of MRONJ but that risk is small
give personalised OHI
prioritise care which reduces mucosal trauma
liaise with specialists
what do you do for a low risk patient who requires an extraction
discuss risks and benefits of extraction
no antibiotic prophylaxis
contact practice if they have concerns
review healing if extraction socket not healed at 8 weeks then refer
what do you do if you suspect a patient has spontaneous MRONJ
refer to oral surgery/special care dentistry
what do you do if a high risk MRONJ patient requires an extraction
discuss risks and benefits
no antibiotic prophylaxis
contact practice if have concerns
review healing at 8 weeks then refer
what are the signs and symptoms of MRONJ
delayed healing following dental extraction
pain
soft tissue infection and swelling
numbness
paraesthesia
exposed bone
what is the hypothesised aetiology for MRONJ
suppression of bone turnover
inhibition angiogenesis
toxic effects on soft tissue
inflammation or infection
what is the risk of MRONJ in cancer patients
1%
what is the risk of MRONJ in osteoporosis patients
0-0.1%
what is the function of anti-resorptive drugs
inhibit osteoclast differentiation and function leading to decreased bone resorption and remodelling
what are the 2 main anti-resorptive drugs associated with osteonecrosis of the jaw
bisphosphonates and denosumab
how do bisphosphonates work
reduce bone resorption by inhibiting enzymes essential to the formation, recruitment and function of osteoclasts
how long do bisphosphonates stay in the body system for
10 years
what kind of drug is denosumab
monoclonal antibody
how does denosumab work
inhibits osteoclast function and associated bone resorption by binding to RANKL
how long does denosumab effects stay in the body
9 months